Elena R. Meskina

Elena R. Meskina

Auto-generated profile, based on publicly available information

Elena R. Meskina

Moscow Regional Research and Clinical Institute (MONIKI)

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 July 2018 in Virologica Sinica
Verified
Journal Article
Closed access
PDF file
VKVictoria Kiseleva
Victoria Kiseleva
EFEvgeny Faizuloev
Evgeny Faizuloev
EMElena Meskina
Elena Meskina
AMAnna Marova
Anna Marova
AOAlexey Oksanich
Alexey Oksanich
VZVitaly Zverev
Vitaly Zverev

15 April 2021 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
PDF file
EMElena R. Meskina
Elena R. Meskina
ETElena E. Tselipanova
Elena E. Tselipanova
MKMarima K. Khadisova
Marima K. Khadisova
LGLidiya A. Galkina
Lidiya A. Galkina
TSTatyana V. Stashko
Tatyana V. Stashko
Aim. To determine the clinical efficacy and safety of the sorbed probiotics Bifidobacterium bifidum 1 (5108 KОЕ) and B. bifidum 1 (5107 KОЕ) in combination with Lactobacillus plantarum 8P-А3 in the complex therapy of pneumonia caused by SARS-CoV-2 in adult patients without severe risk factors. Materials and methods. An open, randomized prospective study included 100 patients (45 men, 55 women), aged 18 to 60 years without risk factors for severe COVID-19 with pneumonia confirmed by computed tomography, and an area of lung lesion no more than 75% (moderate forms). SARS-CoV-2 RNA in nasal and oropharyngeal swabs (RT-PCR) was detected in 72% of the participants, in the rest it was highly probable in terms of the aggregate parameters. Diagnostics of COVID-19 and its severity, the appointment of a standard examination and treatment were carried out in accordance with the Temporary Methodological Recommendations of the Ministry of Health of Russia, version 8 of 09.03.2020. This publication presents the results of using B. bifidum 1 (3 capsules twice a day for 10 days) during the peak of clinical manifestations (in a hospital). Results. In those who received sorbed B. bifidum 1, by the 10th day of treatment, the frequency of weakness was 32% lower (RR 0.55 [95% CI 0.240.73], OR 0.25 [0.110.59]); hypoosmia/dysgeusia by 22% (RR 0.42 [0.050.65], OR 0.40 [0.170.90]) and cough by 24% (RR 0.39 [0.070.60], OR 0.38 [0.170.84]). B. bifidum 1 reduced the average duration of weakness by 3 days [1.14.9], hypoosmia/dysgeusia by 3.2 days [1.35.1], cough by 1.9 days [0.43,4], dyspnea by 1.8 days [0.72.7], diarrhea by 1.7 days [0.13.5]; reduced the risk of antibiotic-associated diarrhea by 20% (RR 0.77 [0.240.93], OR 0.18 [0.050.68]). Due to the deterioration of the condition and the increase in the symptoms of respiratory failure, additional treatment was required less often by 24% (p=0.005). After the end of the intervention, the frequency of virologic debridement, levels of CRP, leukocytes, lymphocytes, platelets and the degree of lung damage on computed tomography did not statistically differ in the compared groups. No side effects of B. bifidum 1 (5108 KОЕ) have been identified. Conclusion. The use of sorbed B. bifidum 1 (5108 KОЕ) improved the well-being of patients without risk factors with moderate viral (SARS-CoV-2) pneumonia and reduced the duration of diarrheal syndrome in a short time. The safety profile of their use was high. More research is needed to clarify the anti-inflammatory effects of the sorbed probiotic.

1 January 2020 in Russian Bulletin of Otorhinolaryngology
Verified
Journal Article
Closed access
EME.R. Meskina
E.R. Meskina
TST.V. Stashko
T.V. Stashko
Острый тонзиллофарингит — один из наиболее частых поводов обращения к врачу и назначения нерациональной антибактериальной терапии (АБТ). Причин этому несколько — от трудностей этиологической диагностики и развития рецидивов и возможных тяжелых осложнений до личностного отношения врачей и пациентов к выбору лечения. Вместе с тем вопрос антибиотикорезистентности и других аспектов, связанных с назначением АБТ, является одной из важнейших проблем современного здравоохранения во всем мире. ЦЕЛЬ ОБЗОРА Продемонстрировать оптимальные практические подходы к выбору тактики лечения острого тонзиллита (ОТ) в лечении детей и взрослых с акцентом на снижение нагрузки АБТ. В обзоре рассмотрены показания и недостатки клинической и лабораторной диагностики ОТ. Не существует высокочувствительных клинических и лабораторных инструментов, которые позволили бы дифференцировать вирусный и бактериальный ОТ. Наложения на миндалинах в детском возрасте не являются основополагающим признаком стрептококкового ОТ. Несмотря на ограничения, в качестве показания для назначения АБТ следует использовать критерий модифицированной шкалы Centor/McIsaac ≥3 (с учетом возраста и наличия респираторных симптомов) в совокупности с быстрым стрептотестом и последующим бактериологическим посевом на S. pyogenes в случае отрицательного результата скринингового теста. Дополнительные обследования (определение лейкоцитоза, СРБ и прокальцитониновый тест) не требуются большинству пациентов. Не следует назначать АБТ пациентам из группы низкого риска для лечения и предотвращения ревматической лихорадки и острого гломерулонефрита. Профилактика гнойных осложнений (паратонзиллита и заглоточного абсцесса, острого среднего отита, шейного лимфаденита, мастоидита или острого синусита) не является специфическим показанием для АБТ при ОТ и не требуется большинству пациентов. Стратегия «бдительного ожидания» с контролем состояния пациентов на 2—3-й день уместна и высокоэффективна в сомнительных случаях. Препаратами выбора лечения ОТ являются амоксициллин и пероральные формы цефалоспоринов I и II поколений. Макролиды в качестве препаратов первой линии лечения ОТ не показаны. Курс АБТ при стрептококковом ОТ составляет 10 дней, что сокращает риски рецидивов. Препараты топического действия могут быть единственным средством этиопатогенетического лечения при вирусном ОТ или дополнительным — при бактериальном ОТ. Их применение не только облегчает боль в горле, но и сокращает продолжительность болезни, а также улучшает прогноз пациентов. Рациональным препаратом выбора топической терапии может быть бензалкония хлорид + тиротрицин + бензокаин (Доритирцин) в связи с имеющимися клиническими доказательствами. Существует весомый резерв для снижения нагрузки АБТ при ОТ. Необходимы дальнейшие клинические исследования, которые бы оценили эффективность коротких курсов АБТ в лечении ОТ в странах с высоким уровнем дохода и были бы основанием для убедительных рекомендаций по применению препаратов топического действия. Это может снизить частоту назначения АБТ и повысить уровень взаимодействия врачей и пациентов.

25 June 2020 in Journal of microbiology, epidemiology and immunobiology
Verified
Journal Article
Open access
PDF file
ЕМЕлена Руслановна Мескина
Елена Руслановна Мескина
Rationale. The novel coronavirus infection caused by SARS-CoV-2 (COVID-19) continues to spread worldwide, though the epidemiological situation varies across countries. It is of interest to estimate the pediatric incidence in a separate constituent entity of the Russian Federation, Moscow Region (MR) closely connected with Moscow (accounting for the highest number of COVID-19 cases in Russia). Assessment of the epidemiological data is interesting due to the late onset of the epidemic outbreak, the preventive lockdown imposed during the early stages, and extensive testing of all the identified contacts.Purpose of the study: Assessment of the pediatric incidence of COVID-19, including identification of its main clinical and epidemiological characteristics, based on the monitoring data for the current situation in MR.Materials and methods. A retrospective analysis of all pediatric cases of laboratory-confirmed COVID-19 in MR (1,047 children of all ages) was performed. The time span covered the data of the daily monitoring of the epidemiological situation from the beginning of reporting (53 days in total). The information was obtained from the database of the Rospotrebnadzor Territorial Administration of MR and collected in compliance with the regulations on Daily Monitoring of Children with Coronavirus Infection, Management Section, State Information System, MR.Results. The pediatric cases of COVID-19 accounted for 6.3% (95% CI2 5.9–6.7) of all the cases reported by 6/5/2020 (16,590); the total infection rate of the pediatric population in the region was 0.07% (0.06–0.09). The basic reproduction number ranged from 4.8 (during the two-week exponential growth phase) to 2.7 (during the later period characterized by a slowdown in the incidence rate) and averaged 3.8 (3.0–4.57). The clustering rate of COVID-19 among children was high, reaching 82.8% (79.7–85.6) with a small average number of cases detected in the cluster — 1.21 (1.16–1.26). Asymptomatic COVID-19 cases prevailed significantly, amounting to 62.2% (59.2–65.1), including 73.1% in newborns; severe cases accounted for 0.38% (0.35–0.41) and hospitalized cases totaled 12.0 (10.1–14.2). No death cases were reported. The mean age of the diseased and infected was 8 [4; 13] years old. Boys prevailed insignificantly (53.2%).Conclusion. There is a distinct stage-by-stage development of the epidemic situation among children in MR. In the pediatric population, COVID-19 was generally acquired from a secondary household transmission within family clusters. Early preventive measures and extensive testing helped to reduce the period of exponential growth and, therefore, to avoid large clusters of infection. In addition, 17.2% of the COVID-19 clusters were identified as those where the child was the first to become sick. In the future, it is necessary to practice distancing and provide effective isolation of diseased children and adults, since the high rate of incidence in children can lag behind the incidence rate in adults.

9 March 2022 in Journal of microbiology, epidemiology and immunobiology
Verified
Journal Article
Open access
PDF file
OPO. A. Petrusha
O. A. Petrusha
EKEkaterina Korchevaya
Ekaterina Korchevaya
RMRamil Mintaev
Ramil Mintaev
ANA. A. Nikonova
A. A. Nikonova
III. Yu. Isakov
I. Yu. Isakov
EFEvgeny Faizuloev
Evgeny Faizuloev
The aim of the study was to analyze genetic characteristics of strains belonging to group A rotaviruses (RVA) circulating in Moscow in 2015–2020, including rare strains non-typeable by polymerase chain reaction (PCR).Materials and methods. A total of 289 stool samples were tested; the samples were collected from children aged 1 month to 17 years, hospitalized with acute gastroenteritis. Immunochromatography and real-time reverse transcription-polymerase chain reaction (real-time RT-PCR) assays were used for detection of rotaviruses in the samples. The rotavirus genome sequencing was performed using the Sanger technique and nanopore sequencing.Results and discussion. RVA RNA was detected in 131 clinical samples, and the G/[P] genotype was identified in 125 samples. The general profile showed prevalence of RVA strains with the G9P[8]I1 genotype (37%) followed by G3P[8]I2, G4P[8]I1, G2P[4]I2, G1P[8]I1, and G3P[8]I1 variants (18, 15, 11, 5, and 2%, respectively). Seven (5%) isolates were identified as GxP[8]. In 2015–2020, the region reported a decline in G4P[8]I1 genotype prevalence (from 39% to 9%) and an increase in the proportion of the G9P[8]I1 genotype (from 6% to 37%) as compared to 2009–2014. In 2018–2020, a large number of cases with the previously unknown DS-1-like reassortant strain with the G3P[8]I2 genotype were reported; the above strain has become widely common worldwide in the recent years. Nanopore sequencing was performed to analyze the genome of the G3P[8]I2 strain and the rare G4P[6]I1 strain. It was found that the G4P[6]I1 strain was phylogenetically related to porcine rotaviruses.Conclusion. In the recent years, the genetic diversity of RVA circulating in the Moscow Region has changed significantly. The obtained results prove the importance of continuous monitoring of rotavirus infection and selective sequencing of RVA genes to fine-tune data of the type-specific real-time RT-PCR. The ever-changing genetic composition of the circulating RVA strains calls for regular optimization of RVA genotyping systems based on real-time RT-PCR.

7 December 2022 in Journal of microbiology, epidemiology and immunobiology
Verified
Journal Article
Open access
PDF file
EMElena R. Meskina
Elena R. Meskina
LGLidiya A. Galkina
Lidiya A. Galkina
ETElena E. Tselipanova
Elena E. Tselipanova
NONuriniso D. Odinaeva
Nuriniso D. Odinaeva
Background. Children and adolescents with infection caused by the hepatitis C virus (HCV) have not been given sufficient attention due to mild forms of HCV and delays in approval of antiviral treatment regimens. Omissions in the studies of pediatric cohorts and shortcomings of management policies aimed at children should be eliminated by improving screening coverage and access to treatment. The aim of the study was to present the results of the cascade sequence of diagnostic testing, care and treatment of children with HCV in the Moscow Region (MR). Materials and methods. The study included all HCV seropositive children of MR (n = 175), who underwent screening tests, and it did not include patients living with HIV/HCV coinfection. Children were observed from 2017 to 2022. The HCV RNA was detected in 164 children and HCV genotypes were identified in 99 children. The stage of liver fibrosis was assessed in 73 children by transient elastography and by FIB-4 index calculation. Results. In MR, 93.7% of seropositive children were tested for HCV RNA; 71.2% of adolescents over 12 years of age received treatment. The prevalence of HCV seropositivity was estimated at 0.113/1,000 children population; the prevalence of chronic HCV infection was at least 0.059/1,000. The dominant HCV subtypes were GT 1b (43.4% [the 95% confidence interval, 33.553.8%]), GT 3a (23.2% [15.332.8%]) and GT 3a/3b (20.2% [12.829.5%]). The incidence of viremic HCV infection per 100,000 children was 3.3 among children under 3 years of age; 7.0 among children aged 36 years; 7.7 among children aged 711 years, 4.4 among adolescents older than 12 years. Natural HCV clearance was reported at the frequency of 19.5% [13.826.4%]. Extrahepatic manifestations were of rare occasion 2.9% [0.96.5%]. Vertical transmission was the primary route of HCV transmission (78.3% [71.484.2%]); infection is assumed to occur during medical invasive procedures 7.4% [4.012.4%], drug using 0.6% [0.013.10%], in the family household 0.6% [0.013.10%]. New cases of HCV infection were more frequently detected during routine examination of children prior to hospitalization or children born to mothers with HCV. Viremic HCV was confirmed in 90.2% [84.694.3%], including HCV infection in 53.4% [45.061.6%], chronic liver disease in 35.8% [28.144.1%] having low activity and occasional consequences (the fibrosis METAVIR score of F1 and F1-2 17.8% [9.828.5%]). No significant clinical and epidemiological differences between the natural course of chronic HCV infection and the liver disease caused by HCV have been found. The burden of pediatric HCV in MR is aggravated by a significant proportion of socially vulnerable patients and patients with comorbid conditions. Conclusion. One of the solutions for detection of new pediatric cases of HCV infection in MR can be offered by improvement of collaboration and continuity of care among healthcare organizations and early treatment of women of childbearing age. Further research is required to evaluate the effectiveness of routine testing of all socially vulnerable pediatric groups. Early application of pan-genotypic antiviral treatment regimens can contribute significantly to control of the HCV infection incidence in children.